GLP1R and hepatocellular carcinoma: Compared with GLP-1 RA no-use, GLP-1 RA use was also associated with a significantly reduced risk of liver-related death (Model 1,2,3,4 aHRs are 0.36, 0.35, 0.35, 0.32), major adverse cardiovascular events (Model 1,2,3,4 aHRs are 0.92, 0.91, 0.92, 0.92), and cardiovascular death (Model 1,2,3,4 aHRs are 0.55, 0.54, 0.55, 0.57), but without significant difference in the risks of cirrhosis development (aHR 1.10, 95%CI 0.88–1.37), hepatic failure (aHR 0.92, 95%CI 0.66–1.30), and hepatocellular carcinoma (aHR 0.91, 95%CI 0.59–1.40).